Research programme: erythropoietin mimetics - Amgen/Celera Genomics

Drug Profile

Research programme: erythropoietin mimetics - Amgen/Celera Genomics

Alternative Names: EPO mimetics - Amgen/Celera Genomics; EPO mimetics - Celera Genomics/Amgen

Latest Information Update: 10 Jul 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; Celera Genomics Group
  • Class Small molecules
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 10 Jul 2001 No-Development-Reported for Anaemia in USA (Unknown route)
  • 04 Nov 1998 Preclinical development for Anaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top